A tumor-sensitive biological metal–organic complex for drug delivery and cancer therapy

2020 ◽  
Vol 8 (32) ◽  
pp. 7189-7196 ◽  
Author(s):  
Zelei Jiang ◽  
Tong Wang ◽  
Shuai Yuan ◽  
Mengfan Wang ◽  
Wei Qi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Cancer Drug ◽  
Organic Complex ◽  
Anti Cancer ◽  
Metal Organic Complex ◽  
Metal Organic ◽  
Inhibition Of Tumor Growth

Tumor-sensitive bioMOC-Zn(Cys) was developed using an endogenous Zn2+ ion and l-cystine for the delivery of anti-cancer drug DOX. In vivo application of DOX@bioMOC-Zn(Cys) shows the increased inhibition of tumor growth and prevented side effects.

Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade

2020 ◽  
Vol 27 ◽  
Author(s):  
Muhammad Sohail ◽  
Wenna Guo ◽  
Zhiyong Li ◽  
Hui Xu ◽  
Feng Zhao ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Research Progress ◽  
Cancer Drug ◽  
Conventional Chemotherapy ◽  
Anti Cancer ◽  
Cancer Drug Delivery

: In recent years, due to the shortcomings of conventional chemotherapy, such as poor bioavailability, low treatment index and unclear side effects, the focus of cancer research has shifted to new nanocarriers of chemotherapeutic drugs. By using biodegradable materials, nanocarriers generally have the advantages of good biocompatibility, low side effects, targeting, controlled release profile, and improved efficacy. And more to the point, nanocarrier based anti-cancer drug delivery systems clearly show the potential to overcome the problems associated with conventional chemotherapy. In order to promote the deepening of research and development in this field, we herein summarized and analyzed various nanocarrier based drug delivery systems for cancer therapy, including the concepts, types, characteristics and preparation methods. The active and passive targeting mechanisms of cancer therapy were also included, along with a brief introduction of the research progress of nanocarriers used for anti-cancer drug delivery in the past decade.

scholarly journals New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1523 ◽  
Author(s):  
Yuanyuan Fu ◽  
Qianqian Gu ◽  
Li Luo ◽  
Jiecheng Xu ◽  
Yuping Luo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Therapeutic Strategy ◽  
Screening Method ◽  
Cancer Drug ◽  
Autophagic Flux ◽  
Single Target ◽  
Anti Cancer

Autophagy inhibition has been proposed to be a potential therapeutic strategy for cancer, however, few autophagy inhibitors have been developed. Recent studies have indicated that lysosome and autophagy related 4B cysteine peptidase (ATG4B) are two promising targets in autophagy for cancer therapy. Although some inhibitors of either lysosome or ATG4B were reported, there are limitations in the use of these single target compounds. Considering multi-functional drugs have advantages, such as high efficacy and low toxicity, we first screened and validated a batch of compounds designed and synthesized in our laboratory by combining the screening method of ATG4B inhibitors and the identification method of lysosome inhibitors. ATG4B activity was effectively inhibited in vitro. Moreover, 163N inhibited autophagic flux and caused the accumulation of autolysosomes. Further studies demonstrated that 163N could not affect the autophagosome-lysosome fusion but could cause lysosome dysfunction. In addition, 163N diminished tumor cell viability and impaired the development of colorectal cancer in vivo. The current study findings indicate that the dual effect inhibitor 163N offers an attractive new anti-cancer drug and compounds having a combination of lysosome inhibition and ATG4B inhibition are a promising therapeutic strategy for colorectal cancer therapy.

Paclitaxel-polyurethane film for anti-cancer drug delivery: Film characterization and preliminary in vivo study

2010 ◽  
Vol 18 (7) ◽  
pp. 680-685 ◽  
Author(s):  
Sung-Gwon Kang ◽  
Se Chul Lee ◽  
Seong Hoon Choi ◽  
Sangsoo Park ◽  
Seok Jeong ◽  
...  
Keyword(s):  
Drug Delivery ◽  
In Vivo Study ◽  
Cancer Drug ◽  
Anti Cancer ◽  
Polyurethane Film ◽  
Cancer Drug Delivery

scholarly journals Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Sonia Iranpour ◽  
Ahmad Reza Bahrami ◽  
Sirous Nekooei ◽  
Amir Sh. Saljooghi ◽  
Maryam M. Matin
Keyword(s):  
Colorectal Cancer ◽  
Drug Delivery ◽  
Side Effects ◽  
Mesoporous Silica ◽  
Cancer Drug ◽  
Delivery Performance ◽  
Anti Cancer ◽  
Cancer Drug Delivery ◽  
Magnetic Mesoporous Silica ◽  
Ht 29

Abstract Background Improving anti-cancer drug delivery performance can be achieved through designing smart and targeted drug delivery systems (DDSs). For this aim, it is important to evaluate overexpressed biomarkers in the tumor microenvironment (TME) for optimizing DDSs. Materials and methods Herein, we designed a novel DDS based on magnetic mesoporous silica core–shell nanoparticles (SPION@MSNs) in which release of doxorubicin (DOX) at the physiologic pH was blocked with gold gatekeepers. In this platform, we conjugated heterofunctional polyethylene glycol (PEG) onto the outer surface of nanocarriers to increase their biocompatibility. At the final stage, an epithelial cell adhesion molecule (EpCAM) aptamer as an active targeting moiety was covalently attached (Apt-PEG-Au@NPs-DOX) for selective drug delivery to colorectal cancer (CRC) cells. The physicochemical properties of non-targeted and targeted nanocarriers were fully characterized. The anti-cancer activity, cellular internalization, and then the cell death mechanism of prepared nanocarriers were determined and compared in vitro. Finally, tumor inhibitory effects, biodistribution and possible side effects of the nanocarriers were evaluated in immunocompromised C57BL/6 mice bearing human HT-29 tumors. Results Nanocarriers were successfully synthesized with a mean final size diameter of 58.22 ± 8.54 nm. Higher cytotoxicity and cellular uptake of targeted nanocarriers were shown in the EpCAM-positive HT-29 cells as compared to the EpCAM-negative CHO cells, indicating the efficacy of aptamer as a targeting agent. In vivo results in a humanized mouse model showed that targeted nanocarriers could effectively increase DOX accumulation in the tumor site, inhibit tumor growth, and reduce the adverse side effects. Conclusion These results suggest that corporation of a magnetic core, gold gatekeeper, PEG and aptamer can strongly improve drug delivery performance and provide a theranostic DDS for efficient CRC therapy. Graphic abstract

scholarly journals Bioorthogonal Photo-Catalytic Activation of an Anti-Cancer Prodrug by Riboflavin

2021 ◽  
Author(s):  
Xin Yang ◽  
Limin Ma ◽  
Hongwei Shao ◽  
Xia Ling ◽  
Mengyu Yao ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Treatment ◽  
Density Functional ◽  
Cancer Drug ◽  
Spatiotemporal Resolution ◽  
Precise Control ◽  
Catalytic Activation ◽  
Anti Cancer

Chemotherapies for cancer treatment usually suffer from poor targeting ability and serious side-effects. To improve the treatment efficiency and reduce side effects, photoactivatable chemotherapy has been recently proposed for precise cancer treatment with high spatiotemporal resolution. However, most photoactivatable prodrugs require decoration by stoichiometric photo-cleavable groups, which are only responsive to ultraviolet irradiation and suffer from low reaction efficiency. To tackle these challenges, we herein propose a bioorthogonal photo-catalytic activation strategy with riboflavin as the catalyst for in situ transformation of prodrug dihydrochelerythrine (DHCHE) prodrug into anti-cancer drug chelerythrine (CHE), which can efficiently kill cancer cells and inhibit in vivo tumor growth under light irradiation. Meanwhile, the photo-catalytic transformation from DHCHE into CHE was in situ monitored by green-to-red fluorescence conversion, which can be used for precise control of the therapeutic dose. The photocatalytic mechanism was also fully explored by means of density functional theory (DFT) calculations. We believe this imaging-guided bioorthogonal photo-catalytic activation strategy is promising for cancer chemotherapy in clinical applications.

Metal–organic complex-based chemodynamic therapy agents for cancer therapy

2020 ◽  
Vol 56 (60) ◽  
pp. 8332-8341
Author(s):  
Eunbin Hwang ◽  
Hyo Sung Jung
Keyword(s):  
Cancer Therapy ◽  
Recent Progress ◽  
Organic Complex ◽  
Feature Article ◽  
Organic Complexes ◽  
Metal Organic Complex ◽  
Metal Organic

This feature article summarizes the recent progress in the study of chemodynamic therapy agents based on metal–organic complexes.

scholarly journals Bioorthogonal Photo-Catalytic Activation of an Anti-Cancer Prodrug by Riboflavin

2021 ◽  
Author(s):  
Xin Yang ◽  
Limin Ma ◽  
Hongwei Shao ◽  
Xia Ling ◽  
Mengyu Yao ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Treatment ◽  
Cancer Drug ◽  
Spatiotemporal Resolution ◽  
Precise Control ◽  
Catalytic Activation ◽  
Anti Cancer ◽  
Targeting Ability

Chemotherapies for cancer treatment usually suffer from poor targeting ability and serious side-effects. To improve the treatment efficiency and reduce side effects, photoactivatable chemotherapy has been recently proposed for precise cancer treatment with high spatiotemporal resolution. However, most photoactivatable prodrugs require decoration by stoichiometric photo-cleavable groups, which are only responsive to ultraviolet irradiation and suffer from low reaction efficiency. To tackle these challenges, we herein propose a bioorthogonal photo-catalytic activation strategy with riboflavin as the catalyst for in situ transformation of prodrug dihydrochelerythrine (DHCHE) prodrug into anti-cancer drug chelerythrine (CHE), which can efficiently kill cancer cells and inhibit in vivo tumor growth under light irradiation. Meanwhile, the photo-catalytic transformation from DHCHE into CHE can be in situ monitored by green-to-red fluorescence conversion, which can be used for precise control of the therapeutic dose. We believe this imaging-guided bioorthogonal photo-catalytic strategy is promising for cancer treatment in clinical applications.

Size and surface controllable metal–organic frameworks (MOFs) for fluorescence imaging and cancer therapy

Nanoscale ◽  
2018 ◽  
Vol 10 (13) ◽  
pp. 6205-6211 ◽  
Author(s):  
Xuechuan Gao ◽  
Ruixue Cui ◽  
Guanfeng Ji ◽  
Zhiliang Liu
Keyword(s):  
Cancer Therapy ◽  
Cancer Cells ◽  
Fluorescence Imaging ◽  
Metal Organic Framework ◽  
Metal Organic Frameworks ◽  
Anti Cancer ◽  
Metal Organic ◽  
Organic Framework

This work presents a novel size and surface controllable metal–organic framework, UIO-66-NH2-FA-5-FAM/5-FU, which possesses the superior characteristics of targeted identification of cancer cells, bioimaging and obvious anti-cancer effects in vivo.

Sign in / Sign up

Export Citation Format

Share Document